Ophthalmology Grand Rounds Guest Speaker:

Zelia Correa, MD, PhD

Professor of Ophthalmology

Director of Ocular Oncology Research

Co-Leader, Melanoma and Ocular Tumors Site-Disease

Group

Bascom Palmer Eye Institute

Sylverster Comprehensive Cancer Center

Learning Objectives

At the conclusion of this presentation, participants should be able to understand:

Review the clinical challenges surrounding uveal melanoma immunogenicity. Discuss the benefits of animal models in uveal melanoma research. Understand the role of HDAC inhibition in BAP1 mutant uveal melanoma.

Dr. Subramanian reports financial relationship as a consultant for ACELYRIN, Alexion Pharma, Amgen, GenSight Biologics, Invex Therapeutics, Kriya Therapeutics, Neurophth Therapeutics and Viridian Therapeutics, an investigator for Amgen, GenSight Biologics, Immunovant, Invex Therapeutics, Neurophth Therapeutics and Viridian Therapeutics, recipient of a research grant from Amgen and a DSMB member for Argenx. Dr. Correa reports financial relationships as a research support recipient from Castle Biosciences, Inc., Ideaya Biosciences Inc., and AURA Biosciences, Inc,. All of the other planners, faculty, or individuals in control of content for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

The University of Colorado Anschutz School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Colorado Anschutz School of Medicine designates this live activity for a maximum of AMA PRA Category 1.5 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.